Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BINCY P ABRAHAM

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1578767166
CMS profile
26529
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$182,698.57

243 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BINCY P ABRAHAM

NPI 1578767166 · CMS profile ID 26529

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578767166?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BINCY P ABRAHAM, NPI 1578767166, CMS profile ID 26529. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578767166?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BINCY P ABRAHAM, NPI 1578767166, CMS profile ID 26529. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578767166?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BINCY P ABRAHAM, NPI 1578767166, CMS profile ID 26529, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1578767166?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

243 matching records · $182,698.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 243 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 243.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $38.6207/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223937990 CMS
ABBVIE INC. $7.0207/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201360035 CMS
Lilly USA, LLC $9.7407/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186525029 CMS
PFIZER INC. $25.0007/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231666117 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14,012.0007/22/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223787059 CMS
Takeda Pharmaceuticals U.S.A., Inc. $47.9007/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224097028 CMS
Takeda Pharmaceuticals U.S.A., Inc. $619.8107/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224098456 CMS
ABBVIE INC. $11.3607/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201360033 CMS
Takeda Pharmaceuticals U.S.A., Inc. $35.0807/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223935174 CMS
Janssen Biotech, Inc. $3.9307/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175060888 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.8807/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223888456 CMS
Janssen Biotech, Inc. $11.5107/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175074712 CMS
Janssen Biotech, Inc. $1,125.0007/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175054794 CMS
ABBVIE INC. $8.8806/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201360031 CMS
Janssen Scientific Affairs, LLC $25.0106/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174198765 CMS
Phathom Pharmaceuticals, Inc. $120.5506/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219243654 CMS
Celltrion USA Inc. $43.9306/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250817509 CMS
Celltrion USA Inc. $0.2106/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250817497 CMS
Celltrion USA Inc. $0.2106/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250817499 CMS
Celltrion USA Inc. $2.1506/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250817501 CMS
Celltrion USA Inc. $18.8206/20/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1250817503 CMS
Celltrion USA Inc. $13,040.0006/20/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1250817505 CMS
Celltrion USA Inc. $12.3006/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250817489 CMS
Celltrion USA Inc. $2.7706/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250817491 CMS
Celltrion USA Inc. $3.1806/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250817493 CMS
Celltrion USA Inc. $0.2206/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250817495 CMS
Celltrion USA Inc. $7.4206/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250817483 CMS
ABBVIE INC. $8.3806/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201360029 CMS
Lilly USA, LLC $2,400.0006/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186467441 CMS
Lilly USA, LLC $2,800.0006/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186488461 CMS
Lilly USA, LLC $2,800.0006/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186525033 CMS
ABBVIE INC. $4,500.0006/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201360025 CMS
ABBVIE INC. $25.4806/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201360027 CMS
PFIZER INC. $12.9106/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228812060 CMS
ABBVIE INC. $12.6506/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201360023 CMS
ABBVIE INC. $14.0006/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201360021 CMS
Janssen Biotech, Inc. $5.1106/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175069695 CMS
Celltrion USA Inc. $118.1206/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250817477 CMS
Celltrion USA Inc. $3,260.0006/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250817479 CMS
ABBVIE INC. $13.9005/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201360019 CMS
PFIZER INC. $7.0705/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228872728 CMS
PFIZER INC. $4,812.0005/28/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1229001272 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.6405/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223923749 CMS
Lilly USA, LLC $2,800.0005/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186488457 CMS
Lilly USA, LLC $3,200.0005/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186535683 CMS
ABBVIE INC. $6.8505/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201360017 CMS
Takeda Pharmaceuticals U.S.A., Inc. $107.1005/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223940705 CMS
PFIZER INC. $14.5305/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231722426 CMS
ABBVIE INC. $19.1205/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201360015 CMS
Janssen Biotech, Inc. $3.3805/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175050406 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $223,148.90 421
PY2020 $115,791.41 124
PY2021 $201,276.87 248
PY2022 $297,424.39 390
PY2023 $343,502.73 388
PY2024 $237,482.30 335
PY2025 $182,698.57 243

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $112,559.31 21
PY2024 Principal investigator $77,242.26 8
PY2023 Principal investigator $101,355.54 37
PY2022 Principal investigator $172,529.59 34
PY2021 Principal investigator $119,772.32 25
PY2020 Principal investigator $138,266.15 41
PY2019 Recipient $2,106.09 2
PY2019 Principal investigator $219,187.81 31

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,062.70 12/19/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202531576
Principal investigator 1 ABBVIE INC. $4,160.61 12/19/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202531578
Principal investigator 1 GENZYME CORPORATION $89.50 11/17/2025 Non-covered Recipient Entity
The Methodist Hospital Research Institute Houston Methodist Research Institute
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226084199
Principal investigator 1 GENZYME CORPORATION $89.50 10/06/2025 Non-covered Recipient Entity
The Methodist Hospital Research Institute Houston Methodist Research Institute
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226084169
Principal investigator 1 ABBVIE INC. $1,269.84 09/18/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202511618
Principal investigator 1 GENZYME CORPORATION $132.05 09/15/2025 Non-covered Recipient Entity
The Methodist Hospital Research Institute Houston Methodist Research Institute
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226084130
Principal investigator 1 ABBVIE INC. $1,739.92 09/11/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202510814
Principal investigator 1 ABBVIE INC. $32.50 09/11/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202510816
Principal investigator 1 GENZYME CORPORATION $695.00 08/04/2025 Non-covered Recipient Entity
The Methodist Hospital Research Institute Houston Methodist Research Institute
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226084209
Principal investigator 1 GENZYME CORPORATION $2,500.00 07/21/2025 Non-covered Recipient Entity
The Methodist Hospital Research Institute Houston Methodist Research Institute
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226084100
Principal investigator 1 GENZYME CORPORATION $132.05 06/23/2025 Non-covered Recipient Entity
The Methodist Hospital Research Institute Houston Methodist Research Institute
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226084103
Principal investigator 1 GENZYME CORPORATION $264.10 04/21/2025 Non-covered Recipient Entity
The Methodist Hospital Research Institute Houston Methodist Research Institute
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226084057
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.83 03/10/2025 Non-covered Recipient Entity
Houston Methodist Hospital
Proof of Clinical Principal in Crohn???s Disease No dispute reported 06/30/2026 1220996392
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.83 03/10/2025 Non-covered Recipient Entity
Houston Methodist Hospital
Proof of Clinical Principal in Crohn???s Disease No dispute reported 06/30/2026 1220996394
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.83 03/10/2025 Non-covered Recipient Entity
Houston Methodist Hospital
Proof of Clinical Principal in Crohn???s Disease No dispute reported 06/30/2026 1220996396
Principal investigator 1 GENZYME CORPORATION $28,838.00 02/24/2025 Non-covered Recipient Entity
The Methodist Hospital Research Institute Houston Methodist Research Institute
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226084053
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $65,314.25 02/07/2025 Non-covered Recipient Entity
Houston Methodist Research Institute
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1235996811
Principal investigator 1 Boehringer Ingelheim International GmbH $695.00 01/22/2025 Non-covered Recipient Entity
Houston Methodist Hospital
A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction tre No dispute reported 06/30/2026 1220683070
Principal investigator 1 Boehringer Ingelheim International GmbH $1,042.50 01/22/2025 Non-covered Recipient Entity
Houston Methodist Hospital
A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction tre No dispute reported 06/30/2026 1220683072
Principal investigator 1 Boehringer Ingelheim International GmbH $2,780.00 01/22/2025 Non-covered Recipient Entity
Houston Methodist Hospital
A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction tre No dispute reported 06/30/2026 1220683074
Principal investigator 1 ABBVIE INC. $1,695.30 01/03/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD) No dispute reported 06/30/2026 1202436563